How to present market research to your board

Guide · Founder · 5 min read · last verified 2026-07-27

Presenting market research to a board is an exercise in provenance. The content of the slide — the size of the opportunity, the shape of the competition, the trend you claim to ride — matters less than whether each statement can survive the follow-up it invites: says who, as of when, and how would we know if it stopped being true. Boards forget most of what they are shown; they remember, for years, the moment a number collapsed under a single question. This piece is about method, deliberately: no example figures appear anywhere in it, because the discipline is identical whatever the numbers on your slide happen to be.

What boards actually do with market slides

The first thing to internalise is that a board slide travels. It is forwarded to co-investors, pasted into diligence rooms, lifted into the next fundraise narrative, and quoted back to you several quarters later by someone who was not in the meeting. A market claim therefore has to carry its own defence, because you will not be standing next to it for most of its life. The second thing: board members pattern-match across a portfolio. Your market slide will be silently compared with the best-sourced one they saw this quarter, and an unlabelled estimate sitting where another company showed a sourced range does not read as confidence. It reads as not knowing the difference.

Every claim carries its source and its tier

The base rule: no naked numbers. Each market claim on the slide gets a footnote naming the source and its date, and you should privately know its tier — primary data you collected, named third-party research, vendor-published material, or the output of your own model. Tiers matter because sources are not interchangeable: a figure lifted from a promotional report and a figure from a methodology-published study may sit in the same font on the same slide, but they will behave very differently under diligence. The grading discipline is laid out in how to tier your research sources; the boardroom application is simply that you grade before the meeting, because the meeting will grade regardless — the only choice is whether you did it first.

Ranges beat point estimates

A point estimate invites a false-precision fight you cannot win: any single number is wrong at some decimal, and a board member who distrusts the third digit will extend that distrust to the whole slide. A range with named drivers inverts the dynamic. State what pushes the bottom of the range and what pushes the top — adoption pace, definition breadth, segment boundaries — and a sceptical question now lands inside your range instead of against it, becoming a conversation about assumptions rather than a challenge to your credibility. That conversation is the one you want, because it is the one you prepared for. A range also signals, cheaply and clearly, that you know market sizing is estimation — which, to an experienced board, is more reassuring than confidence.

A model is a model: label it

Bottom-up market sizing — the TAM, SAM and SOM arithmetic — is a model of your own assumptions, and the cardinal sin of board presentation is dressing a model's output as an external fact. The honest form is explicit: here is who we count as addressable and why, here is the filter that narrows addressable to serviceable, here is the share logic behind the obtainable slice, and therefore our model implies the figure shown. Present it as our model implies, never as the market is. The distinction is not pedantry; a board member who recognises model output presented as discovered fact will quietly discount everything else in the deck, and the ones who have sat through diligence before all recognise it. The full construction method is in how to size a market with sources you can defend; the board-specific rule is to keep the arithmetic in the appendix, visible on request, so the claim and its machinery are never separated.

Pre-empt the diligence question

There is one collision you can predict with near certainty: somebody in the room, or in a diligence process later, will hold your figure next to a published analyst figure and find them different. Left for others to discover, the mismatch reads as either sloppiness or spin — even when it is neither, because analyst figures differ from each other for structural reasons: definition boundaries, timing, method, currency of data. Why analyst market-size numbers disagree unpacks those mechanics. The boardroom move is to run the reconciliation yourself, in advance, and show it: name the well-known figure, state which definitional choices separate it from yours, and say why your scope fits your strategy. A pre-empted discrepancy demonstrates command of the terrain; a discovered one, however innocent, spends your credibility on someone else's definitions.

The appendix is the real deliverable

The slide is a summary; the appendix is the asset. It holds the source table — each claim, its origin, its tier, its date — the assumption list, the model walkthrough, and the definitions of every term the slide uses loosely. Built this way, diligence becomes a forwarding exercise rather than a scramble: the appendix answers questions while you sleep, which is precisely what a travelling slide needs. The practical failure is that appendices get reverse-engineered the night before, reconstructing sources for claims written weeks earlier. The fix is to attach provenance at research time, not presentation time — this is where an evidence-first research platform earns its place in the reporting workflow; Magrios attaches source and date to each claim as the research is produced, so the appendix assembles itself as a by-product instead of a deadline crisis.

A pre-meeting checklist

Run the checklist a week out, not the night before, because the gaps it exposes — an unsourced claim, an unreconciled figure, a model with a buried assumption — are research tasks, not formatting tasks. The board is not testing whether your market is large. It is testing whether you can be trusted to describe uncertainty honestly; the market slide just happens to be where that test is administered.